680 Joural of Nigxia Medical Uiversity 34 7 2012 7 1674-6309 2012 07-0680 - 04 TOPOⅡ ER PR C - erbb - 2 1 1 2 1 1. 750004 2. 710061 DNA Ⅱ TOPOⅡ ER PR c - erbb - 2 Elivisio 166 ER PR C - erbb - 2 DNA TOPOⅡ 166 ER PR c - erbb - 2 DNA TOPOⅡ 72. 9% 121 /166 63. 2% 105 /166 50. 0% 83 /166 44. 6% 74 / 166 c - erbb - 2 TOPOⅡ P < 0. 05 ER PR 50 < 50 c - erbb - 2 > 2cm 2cm P < 0. 05 ER PR c - erbb - 2 TOPOⅡ P < 0. 05 TOPOⅡ ER PR P < 0. 05 C - erbb - 2 TOPOⅡ P < 0. 05 c - erb - B2 TOPOⅡ C - erbb - 2 TOPOⅡ R737. 9 A 1 1. 1 166 Estroge Receptor ER Progesteroe Receptor PR 50 ± 10. 4 150 25 ~ 81 ER PR 3 4 9 c - erbb - 2 4% > 5cm 20 1 DNA 1. 2 ER PR C - erbb - 2 TOPOⅡ Ⅱ topoimeraseⅡ TOPOⅡ DNA 1D5 1A6 CB11 STOVT3D1 EliVisio 1. 3 Eliviso ER PR C - erbb - 2 4μm TOPOⅡ H 2 O 2 10mi PBS 3 10mi 4 EliVisio 60mi DAB PBS 2012-03 - 21 NZ1085 1981-1963 - E - mail xxyy@hotmail. com 1. 4 ER PR 11 3 4 C - erbb - 2 15 4 TOPOⅡ 1 7 4 C - erbb - 2 TOPOⅡ
7. TOPOⅡ ER PR C - erbb - 2 681 ER PR 10% + < < 0. 05 ER PR 50 10% - 2 12 4 6 8 4 1 ER PR 1. 5 SPSS 17. 0 c - erbb - 2 TOPOⅡ χ 2 Pearso % ER PR c - erbb - 2 TOPOⅡ 2 20 14 70. 0 15 75. 0 2 10. 0 4 20. 0 166 121 72. 9 105 63. 2 83 50. 0 74 44. 6 2. 1 ER PR c - erbb P 0. 799 0. 336 0. 001 0. 028-2 TOPOⅡ ER PR < 50 χ 2 = 26. 485 36. 862 P < 0. 05 P > 0. 05 c - erbb - 2 P > 0. 05 c - erbb - 2 TOPOⅡ > 2cm P < 0. 05 1 2. 2 ER PR c - erbb - 2 TOPOⅡ 2cm χ 2 = 16. 460 P < 0. 05 c - erbb - 2 ER PR c - erbb - 2 P > 0. 05 TOPOⅡ TOPOⅡ P > χ 2 = 18. 975 16. 229 20. 859 χ 2 0. 05 = 7. 702 P 2 2 ER PR c - erbb - 2 TopoⅡ ER PR C - erbb - 2 TopoⅡ / / / / % % % % / 50 91 81 89. 0 81 89. 0 50 54. 9 40 43. 9 < 50 75 40 53. 3 34 45. 3 33 44. 0 34 45. 3 / cm > 2 90 70 77. 8 64 71. 1 58 64. 4 45 50. 0 2 76 51 67. 1 51 67. 1 25 32. 9 29 38. 2 97 83 87. 3 79 83. 2 63 66. 2 52 54. 7 69 38 55. 1 36 52. 1 20 29. 0 22 31. 9 150 110 73. 3 104 69. 3 78 52. 0 64 42. 7 9 7 77. 8 7 77. 8 3 33. 3 4 44. 4 4 2 50. 0 2 50. 0 1 25. 0 1 25. 0 3 2 66. 7 2 66. 7 1 33. 3 2 66. 7 < 50 2cm P < 0. 05 2. 3 ER PR c - erbb - 2 TOPO Ⅱ TOPOⅡ ER PR TOPO TOPOⅡ + - /% χ2 P Ⅱ ER PR χ 2 = 5. 943 χ 2 ER + 121 47 74 38. 8 = 9. 834 P < 0. 05 5. 943 0. 022 ER - 55 27 18 49. 1 TOPOⅡ ER PR PR + 115 42 73 36. 5 9. 834 0. 002 γ = - 0. 189 γ = - 0. 243 C - erbb - 2 PR - 51 32 19 62. 7 TOPOⅡ c - erbb - 2 + 83 49 34 59. 0 4. 045 0. 000 C - erbb - 2 χ 2 = 14. 045 c - erbb - 2-83 25 58 30. 1 EP PR ER PR 3 ER PR c - erbb - 2 P < 0. 05 r = 0. 291 3 ER PR ER PR
682 34 C - erbb - 2 13 C - erbb - 2 3 ER PR TOPOⅡ ER PR 5 C - erbb - 2 TOPOⅡ 4 Topo Ⅱ α C - erbb - 2 HER - 2 /eu CerbB - 2 185kDa 5 ER PR C - erbb - 2 TOPOⅡ C - erbb - 2 c - erb - B2 TOPO C - erbb - 2 Ⅱ ER PR C - erbb - 2 TOPOⅡ C - erbb - 2 1 Slamo DJ Leylad Joes B Shak S et a1. Use of chemotherapy plus a moocloal atibody agaist HER2 for metastatic breast cacer that over expresses HER2 C - erbb - 2 6-8 J. Egl Med 2001 344 11 783-792. C - 2 Ma Y Lespagard L Durbecq V et al. Polysomy17 i erbb - 2 Her - 2 /eu status elaboratio i breast cacer effect o daily practice J. Cli Cacer Res 2005 11 12 9 4393-4399. TOPOⅡ α β 3 Caldarella A. Female breast cacer status accordig to DNA DNA ER PR ad HER2 expressio a populatio based a- Topo Ⅱ α alysis J. Pathol Ocol Res 2011 17 3 17q21. 3CerbB - 2 17q21. 1 753-758. TopoⅡα 4. J. 2003 2 25 220-221. 5 Vamesu Sl. Agiogeesis ad c - erbb - 2 HER2 / S G 2 TopoⅡα eu overexpressio status i primary breast cacer patiets a aalysis of 158 eedle core biopsies J. G 1 G 0 10 TOPOⅡ Rom Morphol Embryol 2007. 48 2 121-129. TOPOⅡ 6 Kaptai S Tam LK Che B. HER - 2 /eu ad breast P < 0. 05 cacer J. Diag Mol Pathol 2001 10 139 11 TOPOⅡ 7 Sharifah NA. C - erbb - 2 oco - protei expressio i breast cacer relatioship to tumour characteristics ad TOPOⅡ short - term survival i Uiversiti Kebasaa Malaysia Medical Cetre J. Asia Pac Cacer Prev 2008 9 4 663-670. TOPOⅡ 8 Cordoba O. Complete pathological remissio i a patiet DNA with hormoe - receptor positive ad c - erbb - 2 expressio - egative breast cacer treated with FAC TOPOⅡ TOPOⅡ chemotherapy durig pregacy J. Tumori 2010 96 4 629-632. C - erbb - 2 TOPOⅡ 9 Pritchard KI Shepherd LE. HER2 ad resposiveess 12 of breast cacer to adjuvat chemotherapy J. N Egl J Med 2008 354 20 2103-2111.
7. TOPOⅡ ER PR C - erbb - 2 683 10 Yabuki N. Immuohistochemical study of DNA topoisomerase II i huma gastric disorders J. Am J Pathol 1996 149 3 997-1007. 11 Tokiiwa H. Topoisomerase II alpha expressio ad the Ki - 67 labelig idex correlate with progostic factors i estroge receptor - positive ad huma epidermal growth factor type - 2 - egative breast cacer J. Breast Cacer 2011 14 2 291-294. 12 Taer B. Expressio of c - erbb - 2 ad topoisomerase II alpha i relatio to chemoresistace i ovaria cacer J. Zetralbl Gyakol 2002 124 3 176-183. 13 Campiglio M Somezi G Olgiati C et al. Role of proliferatio i HER2 status predicted respose to doxorubici J. It J Ocol 2003 105 4 568-573. Expressio ad Sigificace of ER PR C - erbb - 2 ad TOPOⅡ i Breast Cacer RONG Xiao - wei ZHAO Xue - ya ZHU Meg XU Yua - yi Nigxia Medical Uiversity Yichua 750004 Abstract Objective To observe the expressio ad sigificace of ER PR C - erbb - 2 ad DNA topoisomerase Ⅱ TOPOⅡ i breast cacer. Methods 166 specimes of breast cacer were icluded. The expressios of ER PR C - erbb - 2 ad TOPOⅡi breast cacer were detected by usig immuohistochemical method. The relatioship betwee the cliicopathological factors was observed. Results I 166 specimes of breast cacer the positive expressio rate of ER PR C - erbb - 2 ad TOPOⅡwas 72. 9% 121 /166 63. 2% 105 /166 50. 0% 83 /166 ad 44. 6% 74 /166 respectively. The positive expressio rates of C - erbb - 2 ad TOPOⅡ i the cacer tissue sigificatly icreased compared with i adjacet ormal breast tissue P < 0. 05 the ER ad PR positive expressio rates of breast cacer patiets aged 50 years or above were sigificatly higher tha those of patiets aged below 50 years the positive expressio rate of c - erbb - 2 i breast cacer patiets with tumor size > 2cm was sigificatly higher tha that of patiets with tumor size 2cm P < 0. 05 ER PR c - erbb - 2 ad TOPO II - positive expressio i breast cacer with lymph ode metastasis were sigificatly higher tha those without lymph ode metastasis P < 0. 05 TOPOⅡad ER PR showed sigificatly egative correlatio P < 0. 05 C - erbb - 2 ad TOPOⅡhad sigificatly positive correlatio P < 0. 05. Coclusio c - erb - B2 ad TOPOⅡ has relatioship with lymphatic metastasis of beast cacer. Key words breast cacer C - erbb - 2 TOPOⅡ GB 3358-82 1 x 珋 M 2 s 3 s r 4 t t 5 F F 6 χ 2 7 r 8 v 9 P P t χ 2 q t χ 2